Lb Pharmaceuticals (LBRX) Capital Expenditures (2024 - 2026)

Lb Pharmaceuticals' quarterly Capital Expenditures came in at $32000.0 in Q1 2026, up 52.38% year-on-year from $21000.0 in Q1 2025, and down 20.0% quarter-over-quarter from $40000.0 in Q4 2025.

Lb Pharmaceuticals has reported Capital Expenditures for 3 years, with the latest figure at $32000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Capital Expenditures rose 52.38% year-over-year to $32000.0; the trailing twelve-month figure through Mar 2026 stood at $331000.0 (changed N/A YoY), and the FY2025 full-year result was $52000.0, down 93.24% from the prior year.
  • Capital Expenditures for Q1 2026 stood at $32000.0, down from $40000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $238000.0 in Q4 2024, with the low at $21000.0 in Q1 2025.
  • Average Capital Expenditures over 3 years is $82750.0, with a median of $36000.0 recorded in 2025.
  • Year-over-year, Capital Expenditures plunged 83.19% in 2025 and soared 52.38% in 2026.
  • Tracing LBRX's Capital Expenditures over 3 years: stood at $238000.0 in 2024, then slumped by 83.19% to $40000.0 in 2025, then declined by 20.0% to $32000.0 in 2026.
  • The last three Capital Expenditures figures came in at $32000.0 (Q1 2026), $40000.0 (Q4 2025), and $21000.0 (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 133.40 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 230.60 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 21.83 Mn
10 Lb Pharmaceuticals 789.92 Mn 789.92 Mn - 32,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 32,000.00
Mar 31, 2026 32,000.00
Dec 31, 2025 40,000.00
Dec 31, 2025 40,000.00
Mar 31, 2025 21,000.00
Mar 31, 2025 21,000.00
Dec 31, 2024 238,000.00
Dec 31, 2024 238,000.00